Cytokines and Atherosclerosis

Tedgui, Alain; Ait‐Oufella, Hafid; Mallat, Ziad

doi:10.1002/9783527629589.ch4

Cited by 5 publications

(7 citation statements)

References 122 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Taken together, these findings indicate that IL-1-dependent inflammation is relatively unchecked during atheroma formation (Pou et al, 2011). Currently, no research has examined if exogenous IL-1R2 can mitigate atherosclerosis, but Tedui et al has shown that administration of IL-1RA to ApoE KO mice decreases lesion size (Tedui et al, 2010). …”

Section: Il-1r2 In Diseasementioning

confidence: 99%

IL-1 receptor 2 (IL-1R2) and its role in immune regulation

Peters

Joesting

Freund

2013

Brain, Behavior, and Immunity

210

162

View full text Add to dashboard Cite

The cytokine IL-1 is critical to the pathogenesis of a variety of human conditions and diseases. Unlike most other cytokines, IL-1 is counterbalanced by two endogenous inhibitors. The functional significance of IL-1 receptor antagonist (IL-1RA) is well documented due to the clinical utilization of the recombinant human IL-1RA analog, anakinra. In contrast, much less is known about the type 2 IL-1 receptor (IL-1R2), which acts as a decoy receptor for IL-1. While IL-1R2 is structurally similar to the type 1 IL-1 receptor (IL-1R1) responsible for IL-1 signal transduction, its truncated cytoplasmic domain and lack of Toll-IL-1 receptor (TIR) region renders IL-1R2 incapable of transmembrane signaling. IL-1R2 competes with IL-1R1 for ligands and for the IL-1R1 co-receptor, IL-1 receptor accessory protein (IL-1RAP). Additionally, IL-1R2 exists in both a membrane bound and soluble form (sIL-1R2) that has biological properties similar to both a decoy receptor and a binding protein. Thus far, IL-1R2 has been implicated in arthritis, endometriosis, organ transplantation, sepsis/sickness behavior, diabetes, atherosclerosis, autoimmune inner ear disease (AIED), Alzheimer’s disease and ulcerative colitis. In this review, we will detail the functional properties of IL-1R2 and examine its role in human disease.

show abstract

Section: Il-1r2 In Diseasementioning

confidence: 99%

IL-1 receptor 2 (IL-1R2) and its role in immune regulation

Peters

Joesting

Freund

2013

Brain, Behavior, and Immunity

210

162

View full text Add to dashboard Cite

show abstract

“…7 Several studies have reported that anti-inflammatory drugs suppress the development of atherosclerosis in New Zealand White rabbits and Watanabe heritable hyperlipidemic rabbits. [8][9][10][11] Asai et al reported that dexamethasone inhibits the formation of foam cells in atherosclerotic lesions.…”

Section: Introductionmentioning

confidence: 99%

Preparation of a complex of dexamethasone palmitate–low density lipoprotein and its effect on foam cell formation of murine peritoneal macrophages†

Tauchi¹,

Takase²,

Zushida³

et al. 1999

Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

In the early progression of atherosclerosis, LDL migrates in the subendothelial space of the artery and plays an important role in foam cell formations of macrophages. LDL may serve as a carrier of site-specific delivery of drugs to atherosclerotic lesions. In this exploratory study, dexamethasone palmitate (DP) was incorporated in LDL, and an inhibitory effect of this complex on foam cell formations was examined. LDL was isolated from human plasma, and the DP-LDL complex was prepared by incubation in the presence of Celite 545. No degradation nor modification of LDL was observed. The DP/LDL molar ratio of the complex was 35-50:1. Foam cell formations of murine macrophages were induced by incubation with oxidized LDL. When macrophages were pretreated with the DP-LDL complex, accumulation of cholesterol ester in the macrophages induced by oxidized LDL, i.e., an index of foam cell formation, was decreased. These findings indicated that the DP-LDL complex showed similar characteristics to LDL, and the DP-LDL complex inhibited foam cell formations of macrophages in vitro. This study provides the basis for further study of the DP-LDL complex as a drug-carrier complex for treatment of atherosclerosis.

show abstract

“…These receptors trigger several intracellular signaling pathways, which control gene expression through transcription factors such as NF-B and AP-1. TNF may contribute to several pro-atherogenic processes [2]. TNF enhances the ability of monocye/macrophage to oxidize LDL.…”

Section: Pro-atherogenic Signaling Pathwaysmentioning

confidence: 99%

“…Macrophages are the major source of IL-1 and IL-18 in atherosclerosis [2]. However, IL-1 also induces its own production by human smooth muscle cells (SMC) and endothelial cells (EC).…”

Section: Pro-atherogenic Signaling Pathwaysmentioning

confidence: 99%

See 1 more Smart Citation

Cytokines as Regulators of Atherosclerosis in Murine Models

Mallat

Tedgui²

2007

CDT

Self Cite

View full text Add to dashboard Cite

Atherosclerosis is a chronic inflammatory disease of the arterial wall initiated by a variety of pro-atherogenic stimuli, such as modified epitopes of phospholipids. Both innate and adaptive immune responses contribute to disease initiation and progression. Here, we review the major cytokines involved in this immuno-inflammatory response, and shown to significantly impact disease initiation and/or progression in murine models. We particularly emphasize the role of the regulatory arm of the immune response in disease modulation, and review the major factors that may be involved in its promotion or alteration.

show abstract

Cytokines and Atherosclerosis

Cited by 5 publications

References 122 publications

IL-1 receptor 2 (IL-1R2) and its role in immune regulation

IL-1 receptor 2 (IL-1R2) and its role in immune regulation

Preparation of a complex of dexamethasone palmitate–low density lipoprotein and its effect on foam cell formation of murine peritoneal macrophages†

Cytokines as Regulators of Atherosclerosis in Murine Models

Contact Info

Product

Resources

About